Lu et al. [64] discovered that in shikonin-treated glioma cells, inhibition of necroptosis could prevent intracellular ROS production, while mitigation of ROS with a cleaner of mitochondrial superoxide, MnTBAP, could attenuate shikonin-induced glioma cell necroptosis, as well as increase the expressions of RIP1 and RIP3. Here, RIPK1 is linked to central nervous system cancer.